Randomized Phase II JANUS Study of Atacicept in Patients With Immunoglobulin A Nephropathy and Persistent Proteinuria
出版年份 2022 全文链接
标题
Randomized Phase II JANUS Study of Atacicept in Patients With Immunoglobulin A Nephropathy and Persistent Proteinuria
作者
关键词
APRIL/BLyS inhibitor, atacicept, galactose-deficient IgA1, IgA nephropathy, phase II, proteinuria
出版物
Kidney International Reports
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-05-26
DOI
10.1016/j.ekir.2022.05.017
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective
- (2021) Xin Huang et al. Frontiers in Pharmacology
- Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
- (2020) Eric F Morand et al. RHEUMATOLOGY
- Why Target the Gut to Treat IgA Nephropathy?
- (2020) Jonathan Barratt et al. Kidney International Reports
- Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
- (2019) Aliza Thompson et al. Clinical Journal of the American Society of Nephrology
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Update on treatment of immunoglobulin A nephropathy
- (2018) Yue-Miao Zhang et al. NEPHROLOGY
- New insights into the pathogenesis of IgA nephropathy
- (2017) See Cheng Yeo et al. PEDIATRIC NEPHROLOGY
- A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
- (2016) Richard A. Lafayette et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
- (2015) Riccardo Magistroni et al. KIDNEY INTERNATIONAL
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
- (2014) David Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy
- (2014) Yusuke Suzuki et al. Clinical and Experimental Nephrology
- Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
- (2014) Ludwig Kappos et al. LANCET NEUROLOGY
- Prognosis in IgA Nephropathy: 30-Year Analysis of 1,012 Patients at a Single Center in Japan
- (2014) Takahito Moriyama et al. PLoS One
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- An update on the pathogenesis and treatment of IgA nephropathy
- (2012) Joanna K. Boyd et al. KIDNEY INTERNATIONAL
- Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population
- (2011) W. Le et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now